NHRA launches comprehensive system to track, trace the drug from manufacturer to patient

Manama: The National Health Regulatory Authority (NHRA) announced that it is in implementation of Resolution No. 41 of 2017 regarding the “issuance of a tracking and tracing system for the supply chain of medicines within the Kingdom of Bahrain,” a comprehensive electronic system will be implemented to track and trace the drug supply from its production in the factory until its arrival to the patient to ensure that counterfeit drugs do not enter the Kingdom of Bahrain. as well as to ensure that the drug is dispensed according to the required procedures, including controlled drugs.

 

A company, “MVC”, was chosen by the Supreme Council of Health to implement the project. The company will implement and operate a pharmaceutical supply chain tracking platform to ensure that all global pharmaceutical regulatory compliance requirements are met and provide the regulator with physical tracking of all products at every stage of the supply chain from original manufacturing to a point of sale within the Kingdom of Bahrain.

 

Decision 41 regarding issuing a tracking and tracing system for the supply chain of medicines within the Kingdom of Bahrain stipulated that drug manufacturers and distributors shall be committed to using the Global Trade Item Number (GTIN) for all Medicines circulated in the Kingdom, whether they are locally produced or finished products imported from abroad, or Medicines manufactured abroad and packaged in manufacturing sites inside the Kingdom.

 

Specifications are prepared to contain the drug’s GTIN number. And the expiration date of the drug and the operational number (Batch Number). And the serial number of each package (Serial Number).

 

Dr. Maryam Al-Jalahma, CEO of the authority, said: This makes the Kingdom a world leader in stopping the sale of counterfeit medicines and makes the pharmaceutical supply chain for Bahrain safer. We have designed our system according to the European Medicines Verification System where drug manufacturers collectively finance the system based on sales. Without any financial cost to the authority, hospitals, pharmacies and import agents will not have to pay any additional fees.

 

Dr. Mariam Al Jalahma, CEO of the NHRA, stated that; This makes the Kingdom a world leader in stopping the sale of counterfeit drugs and it makes our pharmaceutical supply chain and our citizens safer. We have modeled our system after the European Medicines Verification System where the pharmaceutical manufactures collectively fund the system based on sales. Therefore, no government funds will be used for the system and the hospitals, pharmacies and importing agents will not have to pay any additional fees

 

 

Dr. Mariam Al Jalahma, praised the Supreme Council of Health’s decision to implement such a state-of-the-art solution and the fact that MVC is a Bahraini company.   She went on to explain that Regulators can check authenticity of products to prevent counterfeits.  Retail/Hospital Pharmacies can scan products before dispensing to check against the NHRA/MVC database which will improve patient safety by reducing medical errors and improve accuracy of pharmacy operations.

 

 

Commenting on the new partnership MVC Chairwoman, Sheikha Dheya bint Ebrahim Al Khalifa said, “We have been building a world-class team in Bahrain to position the Kingdom as a world leader in supply chain track and trace systems. I am honored that our solution and team will be implementing this significant project for the Kingdom of Bahrain.  Now with the ongoing pandemic, the availability, authenticity, and safety of pharmaceutical supply chains is a more urgent priority than ever before”.

 

 

MVC’s was formed by Sheikha Dheya bint Ebrahim Al Khalifa in partnership with AVC Global, a leading-edge blockchain enabled supply chain company bringing rfxcel, the global leader in pharmaceutical digital track and trace solutions together here in Manama. MVC’s platform is now available on Amazon Web Service (AWS), Bahrain.

 

It is expected that the actual implementation will start at the beginning of 2021 after the completion of the implementation of the integrated system and linking it to the import and consumption system of the drug originating from the Supreme Council of Health (DUR).

 

 

Source: Bahrain News Agency